The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Outcomes of patients with R/R AML after menin inhibitor failure
In this video, Eytan Stein, MD, Memorial Sloan Kettering Cancer Center, New York, NY, briefly discusses the poor outcomes for relapsed/refractory (R/R) patients with acute myeloid leukemia (AML) after treatment failure on a menin inhibitor, highlighting the lack of effective salvage options. Dr Stein emphasizes the importance of introducing menin inhibitors, such as revumenib, into earlier lines of therapy to avoid the challenges associated with treating R/R disease. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So after a menin inhibitor, our group recently published a manuscript in Blood Advances showing that after a menin inhibitor failure, patients with acute myeloid leukemia do just terribly. We really don’t have any good salvage options for those patients. That’s why it’s so important, I think. I think what our manuscript highlights is that it’s important to take Revumenib and move it into earlier lines of therapy or other menin inhibitors to earlier lines of therapy because we don’t want to wait for relapsed and refractory disease...
So after a menin inhibitor, our group recently published a manuscript in Blood Advances showing that after a menin inhibitor failure, patients with acute myeloid leukemia do just terribly. We really don’t have any good salvage options for those patients. That’s why it’s so important, I think. I think what our manuscript highlights is that it’s important to take Revumenib and move it into earlier lines of therapy or other menin inhibitors to earlier lines of therapy because we don’t want to wait for relapsed and refractory disease. At that point, the horse is out of the barn.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
